【精选】Rifaximin Treatment Period According to Lactulose Breath.pdfVIP

ORIGINAL ARTICLE Gastroenterology Hepatology /10.3346/jkms.2057 • J Korean Med Sci 2015; 30: 757-762 Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects 1 2 Suhyun Bae, Kwang Jae Lee, Small intestinal bacterial overgrowth (SIBO) can partly explain irritable bowel syndrome 3 1 Young-Sang Kim, and Kyu-Nam Kim (IBS), and rifaximin has been observed to improve abdominal symptoms in nonconstipated 1 IBS patients. However, there are few reports on the association of the rifaximin treatment Department of Family Practice and Community periods with the results of a lactulose breath test (LBT). Therefore, we performed a 2 Health, Department of Gastroenterology, Ajou 3 retrospective review of patient charts to investigate the relation between the rifaximin University School of Medicine, Suwon; Department of Family Medicine, Cha University, Cha Bundang treatment periods with LBT results in nonconstipated IBS patients. We also evaluated the Medical Centre, Seongnam, Korea time to achieve a symptomatic improvement in the IBS patients as compared to the Received: 20 October 2014 changes in the LBT. We reviewed the charts for patients who showed IBS symptoms with Accepted: 28 January 2015 documented positive results for LBT during their initial visit and who had a follow-up LBT after treatment with rifaximin. The LBT values were compared to the subjects’ symptom Address for Correspondence: scores. A total of 102 subjects had a fol